BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Molecular Devices, Inc. (MDCC) Introduces ScreenWorks Peak Pro Software Enabling High Throughput Cardiotoxicity Screening


2/14/2012 9:37:25 AM

Sunnyvale, CA — February 14, 2012 —Molecular Devices, LLC, introduces the ScreenWorks® Peak Pro™ Analysis Module for the FLIPR® Tetra System. The software offers the ability to analyze multi-peak calcium oscillation responses of cells, and in particular beating cardiomyocytes, to characterize cardiotoxic and cardioactive compounds during a high throughput screen.

ScreenWorks Peak Pro analysis module allows easy access to measurement of cardiomyocyte beat rate, as well as temporal characteristics of peaks including rise, decrease, and amplitude. These features are important for researchers to better understand in vitro cardiomyocyte function and the impact of toxic compounds that induce cardiac abnormalities. With ScreenWorks Peak Pro, the FLIPR Tetra System offers the potential to perform safety testing such as cardiotoxicity early in the drug discovery pipeline, thereby allowing researchers to fail toxic compounds sooner, and prioritize the most promising leads to take forward.

The system allows users to estimate efficacy and dosing of a drug candidate prior to progression into clinical studies. Both SAR and medicinal chemistry studies can be directed on a larger scale, when compared to more labor intensive traditional assay methods. The software enables increased throughput and cuts time to results by rapidly delivering advanced and simplified data analysis for multiple parameters in less than five minutes.

The ScreenWorks Peak Pro analysis module, when used with the FLIPR Tetra System and the FLIPR Calcium 5 Assay Kit, provides a robust, high throughput screening method for changes in intracellular calcium associated with cardiomyocyte contractions. Integrated fluidics enables simultaneous evaluation of up to 1536 wells in less than two minutes, and therefore gives users the ability to determine the immediate impact of compounds on cells. This method may be used with both primary and stem-cell derived, human and mouse cardiomyocytes.

“Scientists would previously have to manually count cardiomyocyte cell beats, or export the data to third party software, which was either costly or provided minimal analysis,” said Debra Gallant, Product Manager, Molecular Devices. “This module offers a real advantage to scientists investigating cellular responses, giving rapid, easy analysis and the ability to reject unsuitable or cardiotoxic compounds at an early stage.”

About Molecular Devices, LLC

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics

Molecular Devices is committed to the continual development of innovative solutions for life science applications. The Company is headquartered in Silicon Valley with offices around the globe.

For more information about the complete product portfolio, visit www.moleculardevices.com

Molecular Devices, the Molecular Devices logo, and all other trademarks are the property of Molecular Devices, LLC

Media Contacts:

Jennifer McKie

Molecular Devices

Tel: +1 408 747 1700

Email: Jennifer.McKie@moldev.com

Katie Odgaard

Zyme Communications

Tel: +44 (0)7787 502 947

Email: Katie.odgaard@zymecommunications.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES